Chadwick Jeremy G 4

What Happened
Jeremy G. Chadwick, Kymera Therapeutics’ Chief Operating Officer, exercised 20,000 stock options at $43.50 per share (cost = $870,000) on March 11, 2026 and sold a total of 25,758 shares that same day for aggregate proceeds of approximately $2,145,673. The filing also reports a conversion/disposition of 20,000 derivative shares at $0.00 (no proceeds) in the same transaction group. The activity was effected under a Rule 10b5‑1 trading plan.

Key Details

• Transaction date: March 11, 2026; filing date: March 11, 2026 (same day).
• Option exercise: 20,000 shares @ $43.50 (acquired) — total exercise cost $870,000.
• Sales (open market): 1,765 shares @ weighted avg $82.13 (range $81.47–$82.46) = $144,955; 12,882 shares @ weighted avg $83.10 (range $82.47–$83.46) = $1,070,511; 11,111 shares @ weighted avg $83.72 (range $83.47–$84.21) = $930,207. Total shares sold = 25,758; total proceeds ≈ $2,145,673.
• Additional derivative entry: 20,000 shares reported as exercised/converted and disposed at $0.00 (no proceeds).
• Plan/footnotes: Transactions were under a Rule 10b5‑1 trading plan dated Dec 10, 2025 (F1). Sales prices are reported as weighted averages with ranges in footnotes (F2–F4). Vesting note: related options vest monthly over 36 months beginning Mar 1, 2024 (F5).
• Shares owned after the transactions: not specified in this filing.
• Timeliness: filing appears timely (reported and filed same day).

Context
Because the option exercise and share sales occurred the same day and under a 10b5‑1 plan, this is consistent with a cashless or partial cashless exercise pattern (exercising options and selling shares, often to cover exercise cost or taxes). The filing’s $0.00 derivative disposition is recorded but not explained in detail here; the footnotes and filing do not state the exact nature (e.g., withholding, surrender, or conversion). This report is factual disclosure of insider activity, not an explanation of the reporting person's intent.